Codexis, Inc. (CDXS) SEC Filings & Earnings Calls

History of net losses

“We have incurred net losses since our inception, including net losses of $44.0 million, $65.3 million, and $76.2 million for the years ended December 31, 2025, 2024, and 2023, respectively” · word for word

Customer concentration

“For the six months ended June 30, 2026 and 2025, customers that each individually contributed 10% or more of our total revenue accounted for 60% and 43% of our total revenues, respectively.” · word for word

Dependence on third-party manufacturers

“We are dependent on a limited number of third-party contract manufacturers for large scale production of substantially all of our enzymes.” · word for word

Novel technology risk

“Our ECO Synthesis manufacturing platform is designed to enable the commercial-scale manufacture of RNAi and other RNA-based therapeutics through an enzymatic route. While we believe enzymatic nucleic acid synthesis will offer certain improvements over phosphoramidite chemistry... the enzymatic route is novel and has not yet been commercialized.” · word for word

Dependence on successful commercialization of ECO Synthesis platform; revenue still modest and net loss persists.

“The Company will be submitting its application for a building permit for its ECO GMP Manufacturing Center... Full production capability is planned by the end of 2027.” · word for word

Significant dilution of ~20% for existing shareholders from equity offering.

“16,666,667 shares...at $1.50 per Share”

Preliminary results subject to change; no auditor review.

“These amounts are preliminary and subject to completion of the Company’s financial closing procedures” · word for word

Dependence on Merck technology transfer agreement for significant revenue; sustainability uncertain.

“recognition of an additional $6.3 million in revenue from the Merck Technology Transfer agreement” · word for word

ECO Synthesis platform still in development; commercialization and revenue generation uncertain.

“ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics” · word for word

Customer concentration

“Customer A accounted for 44% of total revenues in Q1 2026.”

Cash burn and debt burden

“Net cash used in operating activities was $13.2 million; long-term debt of $40.5 million with 12.7% effective interest rate.”

Revenue concentration on Merck fee

“Operating cash flow improvement driven by $37.8M Merck fee, which may not recur.”

Restructuring execution risk

“Restructuring charges $3.4M in 2025 from workforce reduction.”

Restructuring charges and net loss for FY2025 indicate ongoing cost pressures.

“Restructuring charges of $3.4 million; net loss of $44.0 million.”

Customer concentration

“For the nine months ended September 30, 2025 and 2024, customers that each individually contributed 10% or more of our total revenue accounted for 55% and 43% of our total revenues, respectively.” · word for word

Dependence on third-party manufacturers

“We are dependent upon the performance and capacity of third-party manufacturers for the larger scale manufacturing of the enzymes used in our pharmaceutical and life sciences businesses.” · word for word

High cash burn and going concern risk

“Net cash used in operating activities was $39.5 million for 9M 2025, and the company has an accumulated deficit of $616.4 million.”

Workforce reduction of 24% with $3.5M restructuring charge.

“Implementing a workforce reduction of approximately 24%... will result in the recognition of an additional expense of approximately $3.5 million.” · word for word

CEO transition and COO departure create leadership uncertainty.

“Stephen Dilly transitioning to Chairman; Alison Moore named CEO. Kevin Norrett, COO, exiting.”

Revenue decline due to customer manufacturing schedule variability.

“Total revenues were $8.6 million for Q3 2025 compared to $12.8 million in Q3 2024.” · word for word